Bioisosteric replacements of tyrosine kinases inhibitors to make potent and safe chemotherapy against malignant cells

References

• Ali, H. I., Nagamatsu, T., & Akaho, E. (2011). Structure-based drug design and AutoDock study of potential protein tyrosine kinases inhibitors. Bioinformation, 5(9), 368–374. https://doi.org/10.6026/97320630005368
   PubMedGoogle Scholar
• Balasubramaniyan, S., Irfan, N., Umamaheswari, A., & Puratchikody, A. (2018). Design and virtual screening of novel fluoroquinolone analogs as effective mutant DNA GyrA inhibitors against urinary tract infection-causing fluoroquinolone resistant Escherichia coli. RSC Advances, 8(42), 23629–23647. https://doi.org/10.1039/c8ra01854e
   PubMed Web of Science ®Google Scholar
• Blay, V., Li, M. C., Ho, S. P., Stoller, M. L., Hsieh, H. P., & Houston, D. R. (2020). Design of drug-like hepsin inhibitors against prostate cancer and kidney stones. Acta Pharmaceutica Sinica. B, 10(7), 1309–1320. https://doi.org/10.1016/j.apsb.2019.09.008
   PubMed Web of Science ®Google Scholar
• Breast Cancer: Types of Treatment | Cancer.Net [homepage on the Internet]. n.d. [cited (2019). Nov 18] Retrieved from: https://www.cancer.net/cancer-types/breast-cancer/types-treatment.
   Google Scholar
• Cooper, G. M., & Hausman, R. E. (2000). The development and causes of cancer. The Cell: A Molecular Approach, 2, 719–728.
   Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7, 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• Dhillon, P. K., Mathur, P., Nandakumar, A., Fitzmaurice, C., Kumar, G. A., Mehrotra, R., Shukla, D. K., Rath, G. K., Gupta, P. C., Swaminathan, R., Thakur, J. S., Dey, S., Allen, C., Badwe, R. A., Dikshit, R., Dhaliwal, R. S., Kaur, T., Kataki, A. C., Visweswara, R. N., … Dandona, L. (2018). The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016. The Lancet Oncology,.19(10), 1289–1306. https://doi.org/10.1016/S1470-2045(18)30447-9
   PubMed Web of Science ®Google Scholar
• Drake, J. M., Lee, J. K., & Witte, O. N. (2014). Clinical targeting of mutated and wild-type protein tyrosine kinasess in cancer. Molecular and Cellular Biology, 34(10), 1722–1732. https://doi.org/10.1128/mcb.01592-13
   PubMed Web of Science ®Google Scholar
• Hevener, K. E. (2018). Computational toxicology methods in chemical library design and high-throughput screening hit validation. In Methods in molecular biology (pp 275–285). Humana Press Inc.
   Google Scholar
• Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2019). PubChem 2019 update: Improved access to chemical data. Nucleic Acids Research, 47(D1), D1102–D1109. https://doi.org/10.1093/nar/gky1033
   PubMed Web of Science ®Google Scholar
• Knapton, S. (2016). Chemotherapy warning as hundreds die from cancer-fighting drugs. Telegr. https://www.telegraph.co.uk/science/2016/08/30/chemotherapy-warning-as-hundreds-die-from-cancer-fighting-drugs/.
   Google Scholar
• Knösel, T., Kampmann, E., Kirchner, T., & Altendorf-Hofmann, A. (2014). Tyrosine kinasess in soft tissue tumors. Der Pathologe, 35(S2), 198–201. https://doi.org/10.1007/s00292-014-1958-3
   PubMedGoogle Scholar
• Morando, M. A., Saladino, G., D'Amelio, N., Pucheta-Martinez, E., Lovera, S., Lelli, M., López-Méndez, B., Marenchino, M., Campos-Olivas, R., & Gervasio, F. L. (2016). U (2016) Conformational selection and induced fit mechanisms in the binding of an anticancer drug to the c-Src kinase. Scientific Reports, 6, 24439. https://doi.org/10.1038/srep24439
   PubMed Web of Science ®Google Scholar
• Nagendran, S., Balasubramaniyan, S., & Irfan, N. (2022). Virtually screened novel sulfathiazole derivatives as a potential drug candidate for methicillin-resistant Staphylococcus aureus and multidrug-resistant tuberculosis. Journal of Biomolecular Structure and Dynamics, 1–10. https://doi.org/10.1080/07391102.2022.2079002
   Web of Science ®Google Scholar
• Navabshan, I., Sakthivel, B., Pandiyan, R., Antoniraj, M. G., Dharmaraj, S., Ashokkumar, V., Khoo, K. S., Chew, K. W., Sugumaran, A., & Show, P. L. (2021). Computational lock and key and dynamic trajectory analysis of natural biophors against COVID-19 spike protein to identify effective lead molecules. Molecular Biotechnology, 63(10), 898–908. https://doi.org/10.1007/s12033-021-00358-z
   PubMed Web of Science ®Google Scholar
• Puratchikody, A., Irfan, N., & Balasubramaniyan, S. (2019). Conceptual design of hybrid PCSK9 lead inhibitors against coronary artery disease. Biocatalysis and Agricultural Biotechnology, 17, 427–440.
   Web of Science ®Google Scholar
• Puratchikody, A., Umamaheswari, A., Irfan, N., Sinha, S., Manju, S. L., Ramanan, M., Ramamoorthy, G., & Doble, M. (2019). A novel class of tyrosine derivatives as dual 5-LOX and COX-2/mPGES1 inhibitors with PGE 2 mediated anticancer properties. New Journal of Chemistry, 43(2), 834–846. https://doi.org/10.1039/C8NJ04385J
   Web of Science ®Google Scholar
• Samuels, E. R., & Sevrioukova, I. (2018). Inhibition of human CYP3A4 by rationally designed ritonavir-like compounds: Impact and interplay of the side group functionalities. Molecular Pharmaceutics, 15(1), 279–288. https://doi.org/10.1021/acs.molpharmaceut.7b00957
   PubMed Web of Science ®Google Scholar
• SeeSAR version 9.2; BioSolveIT GmbH (2019). Sankt Augustin, Germany www.biosolveit.de/SeeSAR.
   Google Scholar
• The International Agency for Research on Cancer (IARC) report W. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018 (2018), 13–15.
   Google Scholar
• Thigpen, J. C., Odle, B. L., & Harirforoosh, S. (2019). Opioids: a review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. European Journal of Drug Metabolism and Pharmacokinetics, 44(5), 591–609.
   PubMed Web of Science ®Google Scholar
• Wang, A., Yan, X.-E., Wu, H., Wang, W., Hu, C., Chen, C., Zhao, Z., Zhao, P., Li, X., Wang, L., Wang, B., Ye, Z., Wang, J., Wang, C., Zhang, W., Gray, N. S., Weisberg, E. L., Chen, L., Liu, J., Yun, C.-H., & Liu, Q. (2016). Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget, 7(43), 69760–69769. https://doi.org/10.18632/oncotarget.11951
   PubMedGoogle Scholar
• Wang, Z., & Cole, P. A. (2014). Catalytic mechanisms and regulation of protein kinases. In Methods in enzymology (pp. 1–21). Academic Press Inc.
   Google Scholar